Literature DB >> 31837884

The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis.

Hui Tang1, Xiang Zhou2, Yu Ye1, Yi Zhou1, Chengyu Wu1, Yan Xu3.   

Abstract

Programmed cell death-ligands 1 (PD-L1) is a promising immune target for tumor immunotherapy. We conducted this meta-analysis to investigate association between PD-L1 expression and clinicopathological characteristics of head and neck squamous cell carcinomas (HNSCC). Electronic databases were searched for eligible studies. Hazard ratio (HR) with 95 % confidence interval (CI) were extracted to assess the relationship between PD-L1 expression and overall survival (OS) and disease-free survival (DFS) of patients. Odds ratio (OR) with 95 %CI were applied to assess the association between PD-L1 expression and clinicopathological features. A total of 1729 patients were identified for this meta-analysis. PD-L1 expression was higher in female patients in HNSCC (OR = 0.58, 95 %CI:0.44-0.76). In oral squamous cell carcinoma (OSCC), female(OR = 0.56, 95 %CI: 0.41-0.77)and lower grade(OR = 0.48, 95 %CI: 0.24-0.93)were associated with the higher PD-L1 level. There was no significant association between OS and PD-L1 in OSCC patients (HR = 0.89, 95 %CI: 0.37-2.14). In oropharyngeal squamous cell carcinoma (OPSCC), PD-L1 was overexpressed in younger patients (OR = 0.43, 95 %CI: 0.21-0.86), higher tumor grade (OR = 2.46, 95 %CI: 1.38-4.37)and positive HPV status (OR = 2.09, 95 %CI:1.42-3.07). No significant correlation was detected between PD-L1 expression and OS in OPSCC patients (HR = 0.78, 95 %CI: 0.57-1.06). However, the higher PD-L1 expression in tumor cells indicated a better DFS of OPSCC (HR = 0.34, 95 %CI: 0.18-0.67). This meta-analysis demonstrated that PD-L1 overexpression in HNSCC associated with female patients. However, no significant difference was observed in OS or DFS, except the DFS in OPSCC.
Copyright © 2019. Published by Elsevier GmbH.

Entities:  

Keywords:  Clinicopathology; HNSCC; HPV; Meta-analysis; PD-L1

Year:  2019        PMID: 31837884     DOI: 10.1016/j.prp.2019.152768

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma.

Authors:  Sebastian Blatt; Maximilian Krüger; Constantin Rump; Stefanie Zimmer; Keyvan Sagheb; Julian Künzel
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

2.  Relationships between apparent diffusion coefficient (ADC) histogram analysis parameters and PD-L 1-expression in head and neck squamous cell carcinomas: a preliminary study.

Authors:  Hans-Jonas Meyer; Anne Kathrin Höhn; Alexey Surov
Journal:  Radiol Oncol       Date:  2021-01-20       Impact factor: 2.991

3.  1α,25(OH)2D3(VD3) promotes Raddeanin A-induced anti-proliferative effects on HeLa cell apoptosis and autophagy through negative regulation of HPV18E6-E7/PD-L1/VDR axis.

Authors:  Zhiyu Li; Biyun Xu; Yuexin Sun; Lanbo Zhou; Yue Tao; Wenjun Hou; Jun Bao; Jun Liu; Weixin Fan
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

4.  Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis.

Authors:  Limeng Wu; Canhua Jiang; Zhihui Zhu; Yao Sun; Tao Zhang
Journal:  PLoS One       Date:  2022-07-26       Impact factor: 3.752

Review 5.  Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.

Authors:  Siqing Jiang; Xin Li; Lihua Huang; Zhensheng Xu; Jinguan Lin
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

6.  Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma.

Authors:  Kit Kitichotkul; Nirush Lertprasertsuke; Sompid Kintarak; Surawut Pongsiriwet; Warit Powcharoen; Anak Iamaroon
Journal:  Heliyon       Date:  2022-09-17

7.  Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study.

Authors:  Juan Francisco Peña-Cardelles; José Juan Pozo-Kreilinger; Giovanna Roncador; Jesús Esteban-Hernández; José Ernesto Moro-Rodríguez; Ana Sastre-Perona; Beatriz Castelo-Fernández; José Luis Cebrián-Carretero
Journal:  Biomedicines       Date:  2022-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.